Personalis, Inc.
$14.27-$0.45 (-3.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.3B
- P/E
- -15.6x
- EV / EBITDA
- -16.7x
- Revenue
- $69.6M
- Net margin
- -116.7%
- ROCE
- -29.9%
Price chart
Technical chartScreen technicals →+72.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -10.5%
- 3M
- -15.5%
- 6M
- +79.5%
- 1Y
- +72.3%
- 5Y
- -4.5%
52-week range
Day change -$0.45 (-3.1%) from $15 to $14 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in PSNL, bought on each weekday since 2021.
News & filings
What Personalis filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 81.3 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 6.76 times current liabilities.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Read moreShow less
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
- Sector
- Healthcare
- Shares outstanding
- 102.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.3B
- P/E
- -15.6x
- P/B
- 4.9x
- EV / EBITDA
- -16.7x
- EV / Sales
- 17.0x
- P/S
- 18.2x
- 52-week high
- $18.38
- 52-week low
- $5.04
Profitability
- Operating margin
- -126.4%
- Net margin
- -116.7%
- EBITDA margin
- -101.9%
- ROE
- -31.1%
- ROCE
- -29.9%
- ROIC
- -36.2%
- ROA
- -24.3%
- Asset turnover
- 0.21
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $69.6M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -17.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 2.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -0.0%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$79.5M
Solvency
- Current ratio
- 6.76
- Debt / Equity
- 0.15
- Debt / Assets
- 0.12
- CFO / Net profit
- 0.92
- Cash / Market cap
- 9.8%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $69.7M |
| Cost of revenue | $53.9M |
| Gross profit | $15.8M |
| Operating expenses | $103.8M |
| Research and development | $50.3M |
| Selling, general and administrative | $53.6M |
| Operating income | -$88.1M |
| Interest and other | $6.8M |
| Pretax income | -$81.3M |
| Tax and other | $20.0k |
| Net income | -$81.3M |
Revenue and net profit
Revenue fell 17.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $65.0M | -$113.3M |
| FY2023 | $73.5M | -$108.3M |
| FY2024 | $84.6M | -$81.3M |
| FY2025 | $69.6M | -$81.3M |
Cash flows
FY2025: -$74.9M from operations, -$79.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$70.2M | -$120.1M |
| FY2023 | -$56.3M | -$67.2M |
| FY2024 | -$45.1M | -$46.8M |
| FY2025 | -$74.9M | -$79.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $69.6M-17.7%1Y
- EBITDA
- -$71.0M
- Net profit
- -$81.3M
- Cash from operations
- -$74.9M
- Free cash flow
- -$79.5M
- Revenue CAGR, 3Y
- 2.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $69.6M | -$71.0M | -$81.3M | -$79.5M | -31.1% | -17.7% | -0.0% |
Monthly returns
Month-by-month returns of PSNL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $334.2M |
| Current assets | $267.9M |
| Non-current assets | $66.2M |
| Liabilities | $73.0M |
| Current liabilities | $39.6M |
| Non-current liabilities | $33.4M |
| Equity | $261.2M |
| Paid-in capital | $892.3M |
| Retained earnings | -$631.3M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; PSNL highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Personalis, Inc.PSNLthis company | $1.3B | -15.6x | 4.9x | -31.1% | -16.7x |
| AdaptHealth Corp.AHCO | $1.3B | -18.7x | 0.9x | -4.7% | 6.6x |
| BioLife Solutions, Inc.BLFS | $1.3B | -288.0x | 3.6x | -1.2% | -109.8x |
| Teladoc Health, Inc.TDOC | $1.3B | -6.6x | 1.0x | -14.5% | 9.8x |
| Enovis CorporationENOV | $1.3B | -1.1x | 0.9x | -79.5% | -3.2x |
| Harrow, Inc.HROW | $1.3B | -251.6x | 24.7x | -9.8% | 34.6x |
| Ardent Health, Inc.ARDT | $1.2B | 9.1x | 1.0x | 10.5% | 5.7x |
| Alphatec Holdings, Inc.ATEC | $1.2B | — | 98.1x | -1154.3% | — |
| Inspire Medical Systems, Inc.INSP | $1.2B | 8.4x | 1.6x | 18.6% | 14.3x |
| Peer median | — | -6.6x | 1.3x | -7.2% | 6.6x |
Year-to-date ROI
PSNL since 1 January, against earlier years.
Historical volatility
PSNL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -177.6% |
| FY2023 | -131.0% |
| FY2024 | -80.7% |
| FY2025 | -126.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $69.7M |
| Cost of revenueCost Of Revenue | $53.9M |
| Gross profitGross Profit | $15.8M |
| Operating expensesOperating Expense | $103.8M |
| Research and developmentResearch And Development | $50.3M |
| Selling, general and administrativeSelling General And Administration | $53.6M |
| Total expensesTotal Expenses | $157.7M |
| Operating incomeOperating Income | -$88.1M |
| Interest and other | |
| Pretax incomePretax Income | -$81.3M |
| TaxTax Provision | $20.0k |
| Net incomeNet Income | -$81.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $334.2M |
| Current assetsCurrent Assets | $267.9M |
| Non-current assetsTotal Non Current Assets | $66.2M |
| LiabilitiesTotal Liabilities Net Minority Interest | $73.0M |
| Current liabilitiesCurrent Liabilities | $39.6M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $33.4M |
| EquityTotal Equity Gross Minority Interest | $261.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$75.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$75.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$81.3M |
| Depreciation and amortisationDepreciation And Amortization | $10.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $10.1M |
| Amortization of securitiesAmortization Of Securities | -$4.0M |
| Stock-based compensationStock Based Compensation | $9.4M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | -$10.2M |
| Other non-cash itemsOther Non Cash Items | $1.0M |
| Investing cash flowInvesting Cash Flow | -$22.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$22.6M |
| Capital expenditureCapital Expenditure | -$4.5M |
| Purchase of PP&EPurchase Of PPE | -$4.5M |
| Sale of PP&ESale Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$4.5M |
| Purchase of investmentsPurchase Of Investment | -$210.2M |
| Sale of investmentsSale Of Investment | $192.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$18.1M |
| Financing cash flowFinancing Cash Flow | $130.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $130.3M |
| Debt issuedIssuance Of Debt | $2.6M |
| Debt repaidRepayment Of Debt | -$2.0M |
| Net debt issuedNet Issuance Payments Of Debt | $580.0k |
| Long-term debt issuedLong Term Debt Issuance | $2.6M |
| Long-term debt repaidLong Term Debt Payments | -$2.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $580.0k |
| Shares issuedIssuance Of Capital Stock | $126.8M |
| Common stock issuedCommon Stock Issuance | $126.8M |
| Net common stock issuedNet Common Stock Issuance | $126.8M |
| Stock options exercisedProceeds From Stock Option Exercised | $3.1M |
| Other financing chargesNet Other Financing Charges | -$190.0k |
| Change in cashChanges In Cash | $32.8M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 1.0% |
| Cash at the start of the yearBeginning Cash Position | $93.2M |
| Cash at the end of the yearEnd Cash Position | $126.0M |
| Free cash flowFree Cash Flow | -$79.5M |
| Supplemental |
Learn while you research
Academy chapters picked for Personalis, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read